Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing database cohort study of intracranial hemorrhage risk with vortioxetine vs SSRIs
jRCT2031230194Completed
- Sponsor
- Takeda
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Takeda. Primary endpoints: Number of participants who experienced intracranial hemorrhage in total follow-up period and Incidence rate of intracranial hemorrhage. Started Jun 2024; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2031230194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230194.